Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.71 USD | +3.44% | +3.04% | +16.31% |
May. 06 | VYNE Therapeutics Says US FDA Clears its Investigational New Drug Application for Potential Autoimmune Treatment | MT |
Apr. 04 | Transcript : VYNE Therapeutics Inc. - Special Call |
Evolution of the average Target Price on VYNE Therapeutics Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering VYNE Therapeutics Inc.
Cantor Fitzgerald | |
HC Wainwright | |
Northland Securities |
EPS Revisions
- Stock Market
- Equities
- VYNE Stock
- Consensus VYNE Therapeutics Inc.